At a glance
ClinicalIndex Comparison Record- ✓Histologically documented thyroid cancer with metastases
- ✓Failed radioactive iodine (131I) treatment or 131I is not appropriate therapy (e.g., due to lack of iodine uptake)
- ✕Central lung lesions involving major blood vessels (arteries or veins)
- ✕History of hemoptysis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer Who Are Refractory to or Not Suitable Candidates for 131 I Treatment
In Brief
A Phase 2 clinical trial evaluating AG013736 for Thyroid Neoplasms. Completed, enrolled 60 participants across 9 sites.
Detailed Summary
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that was not controlled by previous treatment with radioactive iodine (131I) or not be good candidates for such treatment. The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic thyroid cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage.
Study Details
Timeline
Interventions
AG013736, tablets 5 mg BID daily until tumor progression or toxicity